GO
Loading...

Enter multiple symbols separated by commas

Glaxo Says New Study Shows No Avandia Heart Risk

A new study of health insurance records of more than 400,000 U.S. diabetics found no higher risk of heart attacks with GlaxoSmithKline'spill Avandia when compared with other oral diabetes drugs, the drugmaker said in documents made public Thursday.

The study also showed no higher rate of coronary revascularization procedures, such as bypass surgery, in patients who took Avandia, the company said.

Glaxo funded the study, which was done by researchers at i3 Drug Safety, a division of health information company Ingenix.

The findings were included in a summary Glaxo provided to the Food and Drug Administration, which is holding an advisory panel meeting on Monday to evaluate Avandia's heart risks.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Santelli Exchange: Housing headwinds

    Mark Hanson, M Hanson Advisors, joins CNBC's Rick Santelli to discuss the housing market and housing prices.

  • CNBC update: Houston flooding

    High water and flooding are making driving impossible for many travelers in the Houston area; Taco Bell and Pizza Hut are getting rid of artificial colors and flavors; and Olive Garden is getting creative with their breadsticks, reports CNBC's Sue Herera.

  • Medallions run over by Uber

    The taxi and limo industry has taken a hit thanks to the rise of Uber and Lyft. Details, with CNBC's Kate Rogers.